Companies › ITM Solucin
2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Oncology, Gastroenterology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 177Lu-edotreotide PRRT Peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors | SSTR2, SSTR5 | Phase 3 | Neuroendocrine Tumors | Jun 2027 |
| Lutetium Lu 177 Edotreotide SSTR-targeting radiopharmaceutical therapy delivering Lu-177 radiation | SSTR | Phase 1 | Somatostatin Receptor Positive | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04919226 | 177Lu-edotreotide PRRT | Phase 3 | Neuroendocrine Tumors | Gastroenterology | Jun 2027 |
| NCT06441331 | Lutetium Lu 177 Edotreotide | Phase 1 | Somatostatin Receptor Positive | Oncology | Jun 2028 |
| NCT03049189 | 177Lu-edotreotide PRRT | Phase 3 | Neuroendocrine Tumors | Oncology | Nov 2029 |
Advanced Accelerator Applications Orano Med RayzeBio Orca Biosystems Camurus
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.